Physician profile

Virginia S Hung

Plastic Surgery · Woburn, MA

NPI 1962460923

$4,053.61

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,525.42
Travel and Lodging$1,311.40

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Trimed, INC. $2,587.89 2024
Sonex Health, INC. $1,180.86 2023-2024 Sx-One Microknife
Pacira Pharmaceuticals Incorporated $90.41 2022-2024 Exparel, Zilretta, Iovera
Pacira Therapeutics, INC. $57.74 2021
Hologic INC $56.72 2021
Axogen $40.78 2023 Avance Nerve Graft
Allergan, INC. $23.30 2020
Acumed LLC $15.91 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Virginia S Hung

$4,053.61

in general payments reported 2019-2025

Years
2019-2024
Top company
Trimed, INC.

https://glasscript.com/doctor/360968/virginia-s-hung

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.